Understanding The Potential Therapeutic Applications of DBNL (G28988)

Target Name: DBNL

NCBI ID: G28988

DBNL

Understanding The Potential Therapeutic Applications of DBNL

DBNL (Drebrin-Like) is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. Its function is not well understood, but it is known to play a role in the development and maintenance of tissues. It is also known as DREB/CBF-like protein 3 (DCLP).

History:

The study of DBNL began in the 1970s when researchers identified it as a protein that was expressed in the brain, heart, and kidneys. Since then, research has continued to explore its functions and potential as a drug target.

Potential Therapeutic Applications:

DBNL has the potential to be a drug target due to its unique structure and its expression in various tissues. Studies have shown that DBNL interacts with various proteins, including the protein known as TrkB. This interaction suggests that DBNL could be a useful drug target for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.

DBNL has also been shown to play a role in the development and maintenance of tissues, including the brain. This suggests that it may be a useful biomarker for the diagnosis and treatment of brain disorders.

Another potential application of DBNL is its role in the regulation of stem cell proliferation. Studies have shown that DBNL can inhibit the activity of a protein called sonic hedgehog, which is involved in the development and maintenance of stem cells. This suggests that DBNL may be a useful drug target for the treatment of stem cell disorders.

Another Potential Application:

DBNL may also be a potential drug target for the treatment of cancer. Studies have shown that DBNL can interact with the protein known as p53, which is involved in the regulation of cell growth and apoptosis. This interaction suggests that DBNL may be a useful drug target for the treatment of cancer.

DBNL is also a good candidate as a biomarker for cancer, as it has been shown to be upregulated in various types of cancer. This suggests that it may be a useful tool for the diagnosis and monitoring of cancer.

Conclusion:

DBNL is a protein that has been identified as playing a role in the development and maintenance of tissues, including the brain. Its interaction with TrkB and its potential as a drug target make it a promising candidate for the treatment of neurodegenerative diseases, cancer, and other disorders. Further research is needed to fully understand its functions and potential as a drug and biomarker.

Protein Name: Drebrin Like

Functions: Adapter protein that binds F-actin and DNM1, and thereby plays a role in receptor-mediated endocytosis. Plays a role in the reorganization of the actin cytoskeleton, formation of cell projections, such as neurites, in neuron morphogenesis and synapse formation via its interaction with WASL and COBL. Does not bind G-actin and promote actin polymerization by itself. Required for the formation of organized podosome rosettes (By similarity). May act as a common effector of antigen receptor-signaling pathways in leukocytes. Acts as a key component of the immunological synapse that regulates T-cell activation by bridging TCRs and the actin cytoskeleton to gene activation and endocytic processes

The "DBNL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DBNL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets